Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
Info & Links
CEO
Robert C. Jahr
Headquarters
111 S. WOOD AVENUE, UNIT #100 ISELIN, NJ 08852, UNITED STATES
Outlook Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
18.28M
Enterprise Value
46.26M
Enterprise Value/EBITDA(ttm)
-0.79
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
317.94%
Operating Margin(ttm)
--
Profit Margin(ttm)
3763.13%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
627.42%
Return on Assets(ttm)
-293.47%
Income Statement
Revenue(ttm)
205.70K
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
-1.18M
EBITDA(ttm)3
-58.82M
Net Income Available to Common(ttm)
-102.86M
Diluted EPS(ttm)
-2.62
Share Statistics
Beta (5Y Monthly)
-0.07
52-Week Change
-85.29%
S&P 500 52-Week Change
15.40%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
83.07M
Dividend Yield
0.00%
Float4
80.74M
% Held by Insiders
2.80%
% Held by Institutions
11.20%
Balance Sheet
Total Cash(mrq)
8.68M
Total Cash Per Share(mrq)
0.10
Total Debt(mrq)
36.66M
Total Debt/Equity(mrq)
-95.10%
Current Ratio(mrq)
0.35%
Quick Ratio(mrq)
0.28%
Book Value Per Share(mrq)
-0.60
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.25
Free Cash Flow(ytd)
-14.94M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.